Ligand Pharmaceuticals
(NASDAQ:LGND)
$73.1284
1.8584[2.61%]
Last update: 4:18PM Get Real Time Here
Consensus Rating1
Buy
Highest Price Target1
$144.00
Lowest Price Target1
$90.00
Consensus Price Target1
$113.80

Ligand Pharmaceuticals Stock (NASDAQ:LGND), Analyst Ratings, Price Targets, Predictions

Ligand Pharmaceuticals Inc has a consensus price target of $113.8, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Benchmark, and HC Wainwright & Co. on February 29, 2024, December 13, 2023, and September 19, 2023. With an average price target of $127.67 between HC Wainwright & Co., Benchmark, and HC Wainwright & Co., there's an implied 74.58% upside for Ligand Pharmaceuticals Inc from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Dec 23
1
Feb
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Benchmark
Barclays
Roth Capital
Stephens & Co.

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Ligand Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/29/2024LGNDBuy Now
Ligand Pharmaceuticals
$73.1396.91%HC Wainwright & Co.
Joseph Pantginis
→ $144ReiteratesBuy → BuyGet Alert
12/13/2023LGNDBuy Now
Ligand Pharmaceuticals
$73.1329.91%Benchmark
Robert Wasserman
→ $95ReiteratesBuy → BuyGet Alert
09/19/2023LGNDBuy Now
Ligand Pharmaceuticals
$73.1396.91%HC Wainwright & Co.
Joseph Pantginis
→ $144ReiteratesBuy → BuyGet Alert
08/23/2023LGNDBuy Now
Ligand Pharmaceuticals
$73.1329.91%Benchmark
Robert Wasserman
→ $95ReiteratesBuy → BuyGet Alert
08/09/2023LGNDBuy Now
Ligand Pharmaceuticals
$73.1396.91%HC Wainwright & Co.
Joseph Pantginis
→ $144ReiteratesBuy → BuyGet Alert
07/25/2023LGNDBuy Now
Ligand Pharmaceuticals
$73.1350.42%Barclays
Balaji Prasad
$120 → $110MaintainsOverweightGet Alert
06/02/2023LGNDBuy Now
Ligand Pharmaceuticals
$73.1396.91%HC Wainwright & Co.
Joseph Pantginis
$135 → $144ReiteratesBuy → BuyGet Alert
02/21/2023LGNDBuy Now
Ligand Pharmaceuticals
$73.1329.91%Benchmark
Robert Wasserman
→ $95Reiterates → BuyGet Alert
12/23/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.1323.07%Roth Capital
Scott Henry
$85 → $90MaintainsBuyGet Alert
11/21/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.1364.09%Barclays
Balaji Prasad
$150 → $120MaintainsOverweightGet Alert
10/25/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.13105.12%Barclays
Balaji Prasad
$157 → $150MaintainsOverweightGet Alert
09/02/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.13139.31%Roth Capital
Scott Henry
$185 → $175MaintainsBuyGet Alert
07/05/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.13114.69%Barclays
Balaji Prasad
$165 → $157MaintainsOverweightGet Alert
05/16/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.1377.77%Stephens & Co.
Jacob Johnson
$153 → $130MaintainsOverweightGet Alert
02/22/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.1377.77%Benchmark
Robert Wasserman
$180 → $130MaintainsBuyGet Alert
02/18/2022LGNDBuy Now
Ligand Pharmaceuticals
$73.13125.63%Barclays
Balaji Prasad
$185 → $165MaintainsOverweightGet Alert
09/22/2021LGNDBuy Now
Ligand Pharmaceuticals
$73.13146.14%Barclays
Balaji Prasad
MaintainsOverweightGet Alert
07/30/2021LGNDBuy Now
Ligand Pharmaceuticals
$73.13159.82%Roth Capital
Scott Henry
MaintainsBuyGet Alert
05/04/2021LGNDBuy Now
Ligand Pharmaceuticals
$73.13159.82%Barclays
Balaji Prasad
MaintainsOverweightGet Alert

FAQ

Q

What is the target price for Ligand Pharmaceuticals (LGND)?

A

The latest price target for Ligand Pharmaceuticals (NASDAQ: LGND) was reported by HC Wainwright & Co. on February 29, 2024. The analyst firm set a price target for $144.00 expecting LGND to rise to within 12 months (a possible 96.91% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Ligand Pharmaceuticals (LGND)?

A

The latest analyst rating for Ligand Pharmaceuticals (NASDAQ: LGND) was provided by HC Wainwright & Co., and Ligand Pharmaceuticals reiterated their buy rating.

Q

When was the last upgrade for Ligand Pharmaceuticals (LGND)?

A

There is no last upgrade for Ligand Pharmaceuticals.

Q

When was the last downgrade for Ligand Pharmaceuticals (LGND)?

A

There is no last downgrade for Ligand Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for Ligand Pharmaceuticals (LGND)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.

Q

Is the Analyst Rating Ligand Pharmaceuticals (LGND) correct?

A

While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a reiterated with a price target of $0.00 to $144.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $73.13, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch